{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Powder&page=25",
    "query": {
      "intervention": "Study Powder",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Powder&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Powder&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T02:09:06.868Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04157348",
      "title": "Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Granulomatous Vasculitis"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Benralizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 140,
      "start_date": "2019-10-29",
      "completion_date": "2026-11-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 9,
      "location_summary": "Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04157348"
    },
    {
      "nct_id": "NCT03034915",
      "title": "A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "UMEC/VI 62.5/25 mcg via ELLIPTA",
          "type": "DRUG"
        },
        {
          "name": "UMEC 62.5 mcg via ELLIPTA",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol 50 mcg via DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Placebo via ELLIPTA",
          "type": "DRUG"
        },
        {
          "name": "Placebo via DISKUS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 2696,
      "start_date": "2017-06-16",
      "completion_date": "2018-06-18",
      "has_results": true,
      "last_update_posted_date": "2020-03-11",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03034915"
    },
    {
      "nct_id": "NCT05841563",
      "title": "Clinical Trial of PM54 in Advanced Solid Tumors Patients.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PM54",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PharmaMar",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2023-04-28",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05841563"
    },
    {
      "nct_id": "NCT02980133",
      "title": "Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Propionate",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Years to 11 Years"
      },
      "enrollment_count": 841,
      "start_date": "2016-12-28",
      "completion_date": "2019-04-13",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 77,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02980133"
    },
    {
      "nct_id": "NCT01156792",
      "title": "Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FP 100",
          "type": "DRUG"
        },
        {
          "name": "GSK2190915 100",
          "type": "DRUG"
        },
        {
          "name": "GSK2190915 300",
          "type": "DRUG"
        },
        {
          "name": "montelukast",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "FP/SAL 100/50",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "12 Years and older · Female only"
      },
      "enrollment_count": 162,
      "start_date": "2010-09",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01156792"
    },
    {
      "nct_id": "NCT03628352",
      "title": "Taste-masking Study for Tricaprilin in Sensory Panelists",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Taste Profile Assessments"
      ],
      "interventions": [
        {
          "name": "Tricaprilin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerecin",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "25 Years to 80 Years"
      },
      "enrollment_count": 9,
      "start_date": "2018-09-10",
      "completion_date": "2019-08-22",
      "has_results": false,
      "last_update_posted_date": "2019-11-06",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 1,
      "location_summary": "Woburn, Massachusetts",
      "locations": [
        {
          "city": "Woburn",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03628352"
    },
    {
      "nct_id": "NCT06372496",
      "title": "Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate",
          "type": "DRUG"
        },
        {
          "name": "Inhaled corticosteroids/long-acting beta-2 agonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1358,
      "start_date": "2024-04-16",
      "completion_date": "2027-06-14",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 36,
      "location_summary": "Centreville, Alabama • Little Rock, Arkansas • Newport Beach, California + 31 more",
      "locations": [
        {
          "city": "Centreville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06372496"
    },
    {
      "nct_id": "NCT05996835",
      "title": "Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Kidney Injury Due to Sepsis"
      ],
      "interventions": [
        {
          "name": "TIN816 70 mg lyophilisate powder",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 316,
      "start_date": "2024-01-18",
      "completion_date": "2026-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Johns Creek",
          "state": "Georgia"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05996835"
    },
    {
      "nct_id": "NCT07281456",
      "title": "Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sjogren's Syndrome"
      ],
      "interventions": [
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Dental and Craniofacial Research (NIDCR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-12-18",
      "completion_date": "2030-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07281456"
    },
    {
      "nct_id": "NCT02561481",
      "title": "Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Sulforaphane",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Years to 12 Years"
      },
      "enrollment_count": 60,
      "start_date": "2015-12",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-11-02T02:09:06.868Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02561481"
    }
  ]
}